SCHEMBL17407192

SCHEMBL17407192

CC(=O)C1(C)CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.43
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
EPHX1 P07099 1/20 0.38
MAPT P10636 2/20 0.37
ALDH1A1 P00352 1/20 0.37
PREP P48147 1/20 0.37
EPHX2 P34913 1/20 0.37
NR1H2 P55055 1/20 0.36
CYP11B2 P19099 1/20 0.36
USP30 Q70CQ3 1/20 0.36
CTSK P43235 1/20 0.36
RECQL P46063 1/20 0.35
MMP2 P08253 1/20 0.35
MMP13 P45452 1/20 0.35
MMP14 P50281 1/20 0.35
ADAM17 P78536 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6943029 0.88 HPGD (0.43) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL20482260 0.88 HPGD (0.43) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL2279068 0.88 HPGD (0.43) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL2228033 0.86 HPGD (0.42) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL3157569 0.85 HPGD (0.41) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL26248898 0.84 HPGD (0.39) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL26248895 0.84 HPGD (0.39) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL12683369 0.83 HPGD (0.47) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL15116747 0.83 USP2 (0.46) HPGDUSP2SMN1; SMN2EPHX1MAPT
SCHEMBL26248955 0.83 HPGD (0.38) HPGDUSP2SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9562044-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2017-02-07 US disclosed
US-20160002218-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002218-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF CHRM3, CHRM2, CHRM5 HPGD 2726/4885USP2 2287/4885SMN1; SMN2 1804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.